Comparison · NCT01205776-13968753
Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With Ischemia Driven Revascularizations (TLR,TVR and Non-TVR)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With Ischemia Driven Revascularizations (TLR,TVR and Non-TVR). Trial comparisons, record NCT01205776-13968753. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01205776-13968753
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00318 | 0.00108 | 0.00932 | wilson | |
| Risk in group 2 | 0.0128 | 0.00732 | 0.0222 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00958 | -0.0192 | -0.00137 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.249 | 0.0706 | 0.881 | log | |
| Odds ratio, group 1 over group 2 | 0.247 | 0.0695 | 0.878 | log | |
| Number needed to treat, for one fewer participant with the outcome on Percutaneous Coronary Intervention (PCI) than on Coronary Artery Bypass Graft (CABG) | 104 | 52 | 727 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Percutaneous Coronary Intervention (PCI) | Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS | 3 | 942 | OG000 |
| Group 2 | Coronary Artery Bypass Graft (CABG) | Those patients receiving Coronary Artery Bypass Graft (CABG) | 12 | 940 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Ischemia Driven Revascularizations (TLR,TVR and Non-TVR)
- Description
A target lesion (vessel) revascularization will be considered ischemia-driven if the target lesion diameter stenosis is ≥ 50% by QCA (analysis segment measurement, involving the lesion itself and 5 mm of proximal and/or distal margin) and any of the following criteria for ischemia are met:~* A positive functional study corresponding to the area served by the target lesion; or~* Ischemic ECG changes at rest in a distribution consistent with the target vessel; or~* Typical ischemic symptoms referable to the target lesion; or~* IVUS of the target lesion with a minimal lumen area (MLA) of ≤ 4 mm\^2 for non left main lesions or ≤ 6 mm\^2 for left main lesions. If the lesions are de novo (i.e. not restenotic), the~* plaque burden must also be ≥ 60%; or~* Fractional Flow Reserve (FFR) of the target lesion ≤ 0.80
- Time frame
- In-hospital (≤ 7 days of index-procedure)
- Population
- ITT population. Subjects without the required follow-up are excluded from the time period.
Source ClinicalTrials.gov
Trial
- Title
- EXCEL Clinical Trial
- NCT number
- NCT01205776
- Phases
- NA
- Conditions
Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Interventions
- Percutaneous Coronary Intervention, CABG
- Lead sponsor
- Abbott Medical Devices
- Results first posted
- 2018-03-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01205776?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01205776-13968753